

September 29, 2021

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sirs,

Sub: Press Release - Aurobindo's French subsidiary, Arrow Generiques SAS, inaugurates its new logistics and industrial site in Lyon.

We enclose a copy of the Press Release that is being issued by the Company in connection with inauguration of new logistics and industrial site by our French subsidiary, Arrow Generiques SAS in Lyon, France.

Please take the information on record.

Thanking you,

**Yours faithfully,
For AUROBINDO PHARMA LIMITED**



**B. Adi Reddy
Company Secretary**

Encl: As above



Hyderabad, Lyon, September 29, 2021

Aurobindo's French subsidiary Arrow inaugurates its new logistics and industrial site in Lyon

Aurobindo Pharma Limited (along with its subsidiaries together referred to as "Aurobindo") is pleased to announce that its French subsidiary Arrow Generiques SAS (Laboratoire Arrow, which is referred to as "Arrow") has announced the opening of its new logistics and industrial site in Saint Vulbas, near Lyon, France. The new facility reflects our strong commitment to the region, will support our growth aspirations in the French market and help in creating 100 new employment opportunities.

The opening ceremony, which took place earlier today, was graced by local and state dignitaries, including his Excellency, the Ambassador of India to France & Monaco, Mr. Jawed Ashra and in the presence of Mr. P. V. Ramprasad Reddy, Founder and Director of Aurobindo and Mr. Vincent Pont, President of Arrow.

The state-of-the-art facility covers a surface area exceeding 25,000 m² and built on a 7-hectare site. The new site has been completed with an investment of over EURO 20 million and is principally dedicated for the storage, preparation and distribution of pharmaceutical products with an additional unit built for future industrial activities.

The site's strategic location in the logistics hubs of the Auvergne Rhône-Alpes region is an advantage, along with the benefit of geographical proximity to Arrow's headquarters in Lyon. The unit will be operated by the logistics service provider GEODIS, continuing its historical partnership with Arrow.

Arrow's new site, which is in the Auvergne-Rhône-Alpes region, has the potential to improve the economic development in the area directly and indirectly through job creation. The facility will also provide the requisite infrastructure to support future growth in the region for Aurobindo, a global leader in the pharmaceutical space.

V.Muralidharan, President, European Operations at Aurobindo Pharma, said: "We are delighted to be reinforcing our commitment to the Auvergne-Rhône-Alpes region with the opening of our new facility in Saint Vulbas, in the heart of Europe, where Arrow is situated. With the help of talent and the resources available in the region, this facility will support our growth plans in the French market. Our investment in this state-of-the-art logistics hub will not only improve access to the Auvergne Rhône-Alpes region but importantly will create new jobs as well. This will help further fulfil our commitment to provide healthier life for patients and communities. We are delighted to welcome the Indian Ambassador to France and Monaco and other guests today to celebrate the opening of our new facility."

About Arrow Generiques SAS

Arrow Generiques SAS is the French subsidiary of Aurobindo Pharma Limited, is headquartered in Lyon, France. It is also referred to locally as Laboratoire Arrow. It markets branded and generic medicines through both retail and hospital channels in France. The company's dynamic growth backed by steady product launches has helped it emerge as a formidable pharmaceutical player in France in the last 20 years. Arrow is one of the top 5 generic pharmaceutical companies in the retail market and is the leading generic player in the hospital market in France.

To know more, please log on to <http://www.laboratoire-arrow.com/>

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad - 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. Off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500038 T.S., INDIA Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833

About Aurobindo Pharma Limited

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 155 countries.

The company has 27 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

To know more, please log on to www.aurobindo.com

For further information or queries, please contact:

Arvind Bothra
Head - Investor Relations | Corporate Communications
Phone: +91 40 66725401 / 66725000
Email: ir@aurobindo.com

Disclaimer:

This press release contain statements that may constitute "forward looking statements" including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward-looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward-looking statements to reflect future events or circumstances and will not be held liable for any use of this information.

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. Off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500038 T.S., INDIA Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833